Table 2.
IPC ID | Site | SIA IC50 (nM) |
RSA (%) | RA (%) |
|||
---|---|---|---|---|---|---|---|
AS | DHA | D3 | D6 | D10 | |||
5145 | Pailin | 0.7 | 0.77 | 14.2 | 1.70 | 3.78 | 47.83 |
4970 | Pailin | 0.8 | 0.34 | 15.5 | NA | NA | NA |
4992 | Pailin | 0.35 | 0.5 | 13.8 | 0.0 | 2.5 | 14.54 |
4248 | Pailin | 0.27 | 0.25 | 7.1 | NA | NA | NA |
5035 | Pailin | 2.92 | 4.79 | 7.1 | NA | NA | NA |
5100 | Pailin | 0.63 | 0.44 | 4.2 | NA | NA | NA |
5160 | Pailin | 0.21 | 0.3 | 19.6 | NA | NA | NA |
5168 | Pailin | 0.37 | 0.45 | 14.2 | NA | NA | NA |
5208 | Pailin | 0.63 | 0.6 | 3.9 | NA | NA | NA |
4971 | Pailin | 1.08 | 1.13 | 17.4 | 0.87 | 3.37 | 77.71 |
5188 | Ratanakiri | 0.31 | 0.2 | 3.3 | NA | NA | NA |
3592 | Ratanakiri | 1.1 | 1,00 | 1.6 | 0.0 | 0.88 | 10.66 |
5150 | Ratanakiri | 0.51 | 0.45 | 0.7 | 0.0 | 0,0 | 2.5 |
5055 | Ratanakiri | 0.31 | 0.32 | 0.16 | NA | NA | NA |
4974 | Ratanakiri | 0.5 | 0.23 | 1.3 | 0.0 | 0.0 | 3.48 |
5152 | Ratanakiri | 0.29 | 0.37 | 0.6 | NA | NA | NA |
5159 | Ratanakiri | 0.45 | 0.4 | 0.6 | NA | NA | NA |
4880 | Ratanakiri | 0.39 | 0.26 | 1.3 | NA | NA | NA |
5207 | Ratanakiri | 0.36 | 0.3 | 1.1 | NA | NA | NA |
4914 | Ratanakiri | 0.37 | 0.32 | 2.5 | NA | NA | NA |
3D7 | Reference clone | 0.58 | 0.47 | 0.8 | NA | NA | NA |
G15 | Reference clone | NA | NA | 3.5 | NA | NA | NA |
W2 | Reference clone | 0.71 | 0.63 | 5.4 | NA | NA | NA |
7G8 | Reference clone | NA | NA | 1.7 | NA | NA | NA |
HB3 | Reference clone | NA | NA | 0.6 | NA | NA | NA |
SIA, standard in vitro drug susceptibility assay; RSA, ring-stage survival assay; RA, recovery assay; AS, artesunate; DHA, dihydroartemisinin; IC50, 50% inhibitory concentration; RSA (%), percentage of viable parasites having developed into a second generation of rings or trophozoites at 66 h following exposure of ring stages; RA (%), percentage of recovery from the initial parasitemia.